DNLI FY 2020 Earnings — Denali Therapeutics Inc. Revenue & Financial Results | Market Cap Arena

DNLIDenali Therapeutics Inc.

$3B

FY 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$336M+1158.2% YoY

Gross Profit

$336M100.0% margin

Operating Income

$63M18.7% margin

Net Income

$71M21.2% margin

EPS (Diluted)

$0.63

Cash Flow

Operating Cash Flow

$416M

Free Cash Flow

$413M

Stock-Based Comp.

$50M

Balance Sheet

Total Assets

$1.6B

Total Liabilities

$454M

Stockholders' Equity

$1.2B

Cash & Equivalents

$507M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$336M	$27M	+1158.2%
Gross Profit	$336M	$27M	+1158.2%
Operating Income	$63M	-$213M	+129.4%
Net Income	$71M	-$198M	+136.0%